Although @entity879 represents a ubiquitous @entity1 health problem, there is a lack of effective therapeutic strategies that have few side  -effects and the precise mechanisms underlying @entity879 are not fully understood. Phosphoinositide 3  -kinase ( @entity3115 ) is a pivotal kinase known to regulate inflammatory responses in @entity99 . Although previous research indicates that @entity3115 is involved in @entity299 , including @entity583 , it currently remains unclear whether the inhibition of @entity3115 is essential for ameliorating the severity of lipopolysaccharide ( @entity17296 )  -induced @entity99 . The aim of the present study was to investigate whether pharmacological blockade of @entity3115 ameliorates the development of @entity17296  -induced @entity19 @entity99 . A @entity19 model of @entity17296  -induced @entity99 was used to investigate the therapeutic effect of the pan  - @entity3115 inhibitor, @entity2306 on @entity19 @entity879 and to investigate potential underlying mechanisms. The current report presents the in vivo role of @entity2306 in protecting the @entity19 from @entity879 . @entity2306 was observed to exert significant protective effects on the liver by reducing the activities of @entity3929 aminotransferase and @entity5906 aminotransferase, as well as by improving the histological architecture of the liver. In @entity17296  -induced @entity99 , treatment with @entity2306 clearly inhibited intrahepatic synthesis of various disease  -relevant proinflammatory cytokines, including @entity5 @entity39 factor  -a, @entity777 , @entity635 and interferon  -y. Furthermore, @entity2306 was observed to significantly inhibit @entity10181 phosphorylation in @entity17296  -injured @entity19 liver samples. Therefore, @entity2306 may protect the liver from @entity17296  -induced injury by inhibition of the @entity10181  -nuclear factor k  -light  -chain  -enhancer of activated B cell dependent signaling pathway. Thus, the current report provides evidence that @entity2306 exerts potent effects against @entity17296  -induced @entity99 , indicating its potential therapeutic value for the treatment of acute @entity99 .

@entity2306 prevents lipopolysaccharide  -induced XXXX in a @entity19 model by suppressing @entity10181 phosphorylation.

@entity1 :: ('9606', 'Species') :: ['human'] @entity3115 :: ('18708(Tax:10090)', 'Gene') :: ['PI3K'] @entity17296 :: ('CHEBI:16412', 'Chemical') :: ['LPS'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse', 'murine'] @entity879 :: ('MESH:D017114', 'Disease') :: ['fulminant hepatitis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity5906 :: ('D001224', 'Chemical') :: ['aspartate'] @entity635 :: ('16176(Tax:10090)', 'Gene') :: ['IL  -1b'] @entity2306 :: ('MESH:C085911', 'Chemical') :: ['LY294002'] @entity777 :: ('16193(Tax:10090)', 'Gene') :: ['interleukin (IL)  -6'] @entity3929 :: ('D000409', 'Chemical') :: ['alanine'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac diseases'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic injury', 'hepatic diseases', 'hepatitis', 'acute hepatic injury'] @entity10181 :: ('18036(Tax:10090)', 'Gene') :: ['IkB']
@entity99 :: (MESH:D056486,Disease) :: ['hepatitis']
